Expertise in
2
conditions

Helen I. Mcshane

Old Road Campus Research Building, Roosevelt Drive, 
Oxford, ENG, GB 
Expertise in
2
conditions
Old Road Campus Research Building, Roosevelt Drive, 
Oxford, ENG, GB 

Overview

Helen Mcshane practices practicing medicine in Oxford, United Kingdom.

Ms. Mcshane is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Pulmonary Tuberculosis, Cerebral Hypoxia, Severe Acute Respiratory Syndrome (SARS), and GTP Cyclohydrolase 1 Deficiency.

She is actively involved in clinical research, co-authoring 194 peer reviewed articles and participating in 5 clinical trials.

Gender

Female

Locations

Old Road Campus Research Building, Roosevelt Drive, Oxford, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Clinical Challenge Study to Evaluate Controlled Human Infection With BCG Administered by the Aerosol Inhaled Route in Historically BCG-vaccinated Healthy Adult Volunteers
A Clinical Challenge Study to Evaluate Controlled Human Infection With BCG Administered by the Aerosol Inhaled Route in Historically BCG-vaccinated Healthy Adult Volunteers
Enrollment Status: Completed
Publish Date: February 06, 2025
Intervention Type: Biological
Study Phase: Phase 1
A Human Challenge Study to Evaluate Innate and Adaptive Immune Responses to a Controlled Human Infection With BCG Administered by the Intradermal or Aerosol Inhaled Route in Healthy, BCG-naïve or Historically BCG-vaccinated, UK Adult Volunteers
A Human Challenge Study to Evaluate Innate and Adaptive Immune Responses to a Controlled Human Infection With BCG Administered by the Intradermal or Aerosol Inhaled Route in Healthy, BCG-naïve or Historically BCG-vaccinated, UK Adult Volunteers
Enrollment Status: Unknown
Publish Date: January 03, 2024
Intervention Type: Other, Biological
Study Phase: Phase 1
A Clinical Challenge Trial to Evaluate Controlled Human Infection With BCG Administered by the Aerosol Inhaled Route Compared With the Intradermal Route in Healthy, BCG-naïve, UK Adult Volunteers
A Clinical Challenge Trial to Evaluate Controlled Human Infection With BCG Administered by the Aerosol Inhaled Route Compared With the Intradermal Route in Healthy, BCG-naïve, UK Adult Volunteers
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Other, Biological
Study Phase: Phase 1
A Phase I Clinical Trial to Compare the Safety and Immunogenicity of Candidate TB Vaccine ChAdOx1 85A Administered by the Aerosol Inhaled Route and the Intramuscular Route in Healthy Adult Subjects
A Phase I Clinical Trial to Compare the Safety and Immunogenicity of Candidate TB Vaccine ChAdOx1 85A Administered by the Aerosol Inhaled Route and the Intramuscular Route in Healthy Adult Subjects
Enrollment Status: Completed
Publish Date: September 25, 2020
Intervention Type: Biological
Study Phase: Early Phase 1
A Phase I Trial to Compare the Safety and Immunogenicity of Candidate TB Vaccine MVA85A Administered by the Aerosol Inhaled Route and the Intramuscular Route in Healthy Adult Volunteers Who Are Latently Infected With Mycobacterium Tuberculosis
A Phase I Trial to Compare the Safety and Immunogenicity of Candidate TB Vaccine MVA85A Administered by the Aerosol Inhaled Route and the Intramuscular Route in Healthy Adult Volunteers Who Are Latently Infected With Mycobacterium Tuberculosis
Enrollment Status: Terminated
Publish Date: August 31, 2020
Intervention Type: Biological
Study Phase: Phase 1
View 4 Less Clinical Trials

194 Total Publications

Correction: Domain arrangement-driven immunogenicity of a computationally designed mRNA vaccine targeting PPE68, IrtA, and PE9 of Mycobacterium tuberculosis.
Correction: Domain arrangement-driven immunogenicity of a computationally designed mRNA vaccine targeting PPE68, IrtA, and PE9 of Mycobacterium tuberculosis.
Journal: Scientific reports
Published: July 27, 2026

Frequently Asked Questions about Helen I. Mcshane

Is Helen I. Mcshane a top-rated expert for Pulmonary Tuberculosis?

MediFind is an objective health platform that identifies experts based on real-world data. Helen I. Mcshane is classified as an Advanced expert for Pulmonary Tuberculosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Helen I. Mcshane participate in research or clinical trials?

Yes. Helen I. Mcshane has published 194 articles and abstracts on conditions like Pulmonary Tuberculosis. You can view a list of Helen I. Mcshane's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Mcshane's expertise for a condition
ConditionClose
      View All 11 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile